Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Right taxation, regulation to help make India gaming hub: report
- Bollywood’s investments in startups sees a sharp dip in 2024 at $3.6 million
- How a Netflix bid for Warner Bros Discovery could reshape India’s entertainment landscape
- By 2035 AI- driven automation to boost manufacturing productivity by up to 40%
